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Ubiquitination and degradation of the Myc onco-protein
are highly regulated events that have an important func-
tion in tumourigenesis. A new study by Rosalie Sears and
colleagues now identiﬁes Axin, a tumour suppressor pro-
tein best known for its role in the Wnt pathway, as a
central co-ordinator of this Myc degradation. Loss-of-func-
tion mutations in Axin, therefore, directly enhance Myc
levels in human tumours.
Ever since the discovery that enhanced expression of a wild-type
MYC gene is sufﬁcient to uncover its oncogenic properties in a
mouse model of B-cell lymphomagenesis (Adams et al, 1985), it has
been accepted in the ﬁeld that the levels of Myc are an important
determinant of normal and pathological cell behaviour.
Consequently, the molecular mechanisms that control Myc protein
levels have been studied in extensive detail, and we now know that
both transcriptional and a plethora of post-transcriptional mechan-
isms regulate Myc levels in normal and in tumour cells.
For example, Myc is a highly unstable protein that is rapidly
turned over by the ubiquitin-proteasome system in normal cells; the
rate of turnover is attenuated in many tumour cells. Although
several ubiquitin ligases have been shown to associate with Myc,
the best understood pathway is the degradation by Fbw7 (Welcker
et al, 2004; Yada et al, 2004). Degradation through this pathway is
initiated by phosphorylation of Myc at serine 62, which serves as a
priming site for binding of Gsk3. Gsk3 then phosphorylates Myc at
threonine 58 and T58-phosphorylated Myc is—after a series of
intermediate steps—recognized by the Fbw7 ubiquitin ligase, lead-
ing to degradation of ubiquitinated Myc through the proteasome.
This pathway offers a prime example of how degradation of Myc
can be disrupted during tumourigenesis: many Burkitt lymphomas
harbour point mutations in Myc at either T58 or S62, leading to
reduced ubiquitination and enhanced stability (Bahram et al, 2000).
One would expect, therefore, that similar mutations could be found
in at least some of the other tumours in which enhanced levels of
Myc have an important function. But this does not appear to be the
case: despite intensive efforts, no point mutations of MYC have
been reported from solid tumours.
So, if point mutants of Myc offer an easy way to enhance protein
levels of this protein during tumourigenesis, then why are they
never found in solid tumours, despite extensive searches? One
answer to this riddle, albeit a partial one, is that other mutations
and changes in gene expression occur that can stabilize Myc and
that may, therefore, alleviate the necessity for further mutations in
Myc itself. Several of these changes affect the kinase cascades that
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Figure 1 The ﬁgure illustrates the role of Axin in degradation of Myc. Axin facilitates phosphorylation of T58 by Gsk3 and the subsequent
de-phosphorylation of S62 by PP2A. Mutations in Axin are found in several tumours and affect different scaffolding roles of Axin, all resulting
in enhanced levels of Myc.
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way is constitutively activated in many tumours by mutations in
receptor tyrosine kinases or by loss of the PTEN phosphatase;
activation of PI3-Kinase leads to inhibition of Gsk3 activity and
subsequently T58 phosphorylation. Similarly, the FBW7 gene is a
tumour suppressor gene that is lost in many, most notably colon,
carcinomas (Rajagopalan et al, 2004). Finally, a de-ubiquitinating
enzyme, Usp28, that antagonizes the function of Fbw7 and stabi-
lizes Myc, is expressed at very high levels in breast and colon
carcinoma (Popov et al, 2007). Potentially, therefore, many of the
mutations found in solid tumours affect Myc turnover, and it is
therefore only the genomically relatively stable lymphomas, which
resort to mutating Myc itself.
In the current issue of the EMBO Journal, Rosalie Sears and
colleagues add an important further piece of evidence to support
this concept. In this paper, Arnold et al show that complex forma-
tion between Myc and Gsk3 (as well as PP2A and Pin1 two other
proteins involved in degradation) is facilitated by the scaffolding
protein, Axin1. Axin1 has a similar role in several signaling path-
ways: it is best known for its role in the Wnt pathway, where it acts
as a platform for Gsk3-mediated phosphorylation of b-catenin,
leading to its degradation by the proteasome pathway. Although
the Wnt pathway is intimately linked to Myc function, it appears
that the function of Axin1 in Myc degradation is mediated by a
complex that is unrelated to that mediating catenin turnover, as a
key component of the latter complex, the APC tumour suppressor
protein, has no role in Myc turnover. Importantly, Axin1 is a tumour
suppressor protein and Arnold et al go on to show that stabilization
of Myc in several tumour cell lines correlates with the presence of
Axin1 mutations that disrupt its ability to act as a scaffold for
degradation of Myc (Figure 1).
These data suggest that an additional class of mutations, which
may be largely undetected, contribute to the stabilization of Myc by
inhibiting Fbw7-mediated degradation of the protein. By further
highlighting this pathway, they also point to what appears to be the
biggest puzzle with regard to our understanding of how this path-
way controls Myc function: the T58A and S62A mutations are not
only more stable but also show a strongly reduced pro-apoptotic
potential; for example, lymphomas that are generated with these
mutants in transgenic mice can arise in the presence of wild-type
p53 and Arf and thus escape the otherwise obligatory mutations in
the p53/Arf pathway, which mediates apoptosis in response to
deregulation of wild-type Myc (Hemann et al, 2005). Furthermore,
these mutations have altered gene-regulatory properties. How does
this ﬁt together? First, it is possible that the mutations that are
selected for during lymphomagenesis affect a hitherto unknown
protein interaction of Myc that just happens to bind in a region of
Myc that also affects turnover. This idea is supported by the
observation that not all mutations of Myc that are found in
Burkitt lymphomas stabilize the protein. Alternatively, ubiquitina-
tion of Myc by Fbw7 not only affects protein turnover but also alters
the functional properties of Myc. Indeed, some recent evidence
suggests that ubiquitination of Myc affects its transcriptional prop-
erties and that not all ubiquitination events target Myc to the
proteasome (Kim et al, 2003; von der Lehr et al, 2003; Adhikary
et al, 2005; Otto et al, 2009). Whatever the exact answer is: the
analysis of Myc ubiquitination and turnover is a key to our under-
standing of the protein and is likely to offer many more surprises.
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